NCT05580250

A Study of LY3526318 in Healthy Male Japanese Participants

A Phase I, Single-Centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of LY3526318, and to Investigate the Effect of LY3526318 on Metformin and Simvastatin Pharmacokinetics in Healthy Male Japanese Participants

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a study of LY3526318 in healthy male Japanese. The main purposes of this study are to: * Assess how safe and well tolerated LY3526318 is when given by mouth. * Measure how LY3526318 affects the kidney and the liver. The study will be conducted in three parts (Part A, Part B, Part C). Participants may only enroll in one part. After screening, the study will last from one to two weeks, depending on part.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3526318	Administered orally.
DRUG	Placebo	Administered orally.
DRUG	Iohexol	Administered intravenously (IV).
DRUG	Simvastatin	Administered orally.
DRUG	Metformin	Administered orally.

Timeline

• Start date: 2022-11-22
• Primary completion: 2022-12-08
• Completion: 2022-12-08
• First posted: 2022-10-14
• Last updated: 2023-01-09

Locations

1 site across 1 country: Japan